Highest-materiality recent filing
Cumberland delays release of FIGHT DMD ifetroban long-term data; no new timeline
Phase 2 FIGHT DMD open-label extension long-term safety/efficacy data for ifetroban not yet available.
Cumberland closes $100M Apotex deal, pays $1.50 special dividend, reports Q2 loss
Closed $100M strategic transaction with Apotex Health; received $111M total including inventory and transition services.
Cumberland Pharmaceuticals declares special dividend of $1.50/share, authorizes $5M buyback
Special cash dividend of $1.50 per share, payable July 31, 2026 to holders of record July 23, 2026.
Cumberland closes $100M sale of branded products to Apotex; retains ifetroban pipeline
Sold Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ for $100M cash.
Shareholders approve sale of Cumberland's FDA-approved products to Apotex
Shareholders voted 10,492,455 For (99.84% of votes cast), 15,904 Against, 1,267 Abstain.
Cumberland Pharma enters $100M strategic transaction with Apotex, reports Q1 revenue $9.1M
Entered $100M cash deal to sell FDA-approved brand portfolio to Apotex Inc.; subject to shareholder approval and closing conditions.
Cumberland Pharma sells commercial products to Apotex for $100M, retains pipeline
Apotex acquires six FDA-approved brands (Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ) for $100M cash.
Cumberland Pharma reports Q4 revenue up 31% to $13.7M; full-year adjusted earnings $1.7M
Full-year 2025 net revenue $44.5M (+18% YoY); net loss improved to $2.9M from $6.5M.
Cumberland Pharma gets FDA Fast Track for ifetroban in DMD heart disease
FDA Fast Track Designation granted for ifetroban targeting fatal heart disease in Duchenne muscular dystrophy.
Cumberland Pharma reports Q3 net loss of $1.9M; YTD revenue up 12% to $30.8M
Net revenue for Q3 2025 was $8.3M; YTD $30.8M (+12% vs. 2024).
Cumberland and RedHill form new jointly owned company; Cumberland provides $4M in investment capital.
Cumberland Pharma reports Q2 revenue up 10% YoY; YTD revenue +23%
Q2 net revenue $10.8M (+10% YoY); YTD net revenue $22.6M (+23%).
Cumberland Q1 revenue $11.7M (+38% YoY), net profit $1.3M; DMD Phase II positive, Vibativ China OK
Net revenue $11.7M vs $8.5M prior year, 38% increase.
Cumberland's ifetroban shows 5.4% cardiac improvement in DMD Phase 2 trial
High-dose ifetroban improved LVEF by 3.3% vs. placebo and 5.4% vs. natural history controls.
Cumberland Pharma Q4 revenue +11.6% to $10.4M; full-year net loss $6.4M
Q4 2024 net revenue $10.4M, up 11.6% YoY; full-year revenue $38M.
Cumberland gets NMPA approval in China for Vibativ; exclusive deal with SciClone
Vibativ (telavancin) approved by China's NMPA for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections.
Cumberland Pharma Phase 2 ifetroban trial meets primary endpoint in DMD heart disease
High-dose ifetroban (300mg/day) produced 3.3% LVEF improvement vs placebo decline of 1.5%, net 4.8% benefit.
FDA approves simplified dosing regimen for Cumberland's Acetadote IV NAC
FDA approved sNDA for Acetadote on Dec 9, 2024; new regimen combines first two bags into a single slower infusion.
Cumberland Pharma Q3 net loss $1.5M; Caldolor study, DMD designations announced
Q3 2024 net revenue $9.1M; net loss $1.5M ($0.11 loss per share); adjusted loss $0.26M ($0.02 per share).
Cumberland announces study showing Caldolor reduces adverse drug reactions vs ketorolac
Study analyzed records of >17M patients; compared 31,046 Caldolor vs 124,184 ketorolac adults.
CMS denies Caldolor separate Medicare reimbursement under NOPAIN Act for CY2025
CMS excluded Caldolor from NOPAIN Act separate payment list announced Nov 1, 2024 for CY2025.
Cumberland Pharma Q2 revenue $9.9M, up 16% sequentially; adjusted earnings positive
Q2 net revenue $9.9M, 16% increase from Q1 2024; year-to-date $18.3M.
Cumberland Pharmaceuticals Q1 net loss $1.9M; revenue $8.5M
Net revenue $8.5M; Kristalose $3.2M, Sancuso $1.8M, Vibativ $1.6M, Caldolor $1.5M.
Net loss $6.3M for 2023, includes $3.3M non-cash charge on product discontinuation; adjusted earnings $2.4M ($0.17/share).
Cumberland Pharma Q2 revenue $10.9M (+6% YoY); net income $0.9M
Q2 net revenue $10.9M (+6% vs prior year, +18% sequential); YTD revenue $20.1M.
Cumberland reports ifetroban well-tolerated with positive trend in DMD trial; no stat-sig
Interim analysis from 25 patients after 6 months; both ifetroban doses well-tolerated.
FDA approval expands Caldolor label to include infants 3 months to 6 months for pain and fever.
Q1 2023 net revenues of $9.2M; net income of $0.2M ($0.01 EPS); adjusted earnings of $1.7M ($0.11 EPS).
NOPAIN Act requires Medicare to provide separate reimbursement for non-opioid pain management products in outpatient hospital and ambulatory surgical center settings.
FDA grants barrier-to-innovation waiver; Cumberland to receive ~$1.9M refund for RediTrex fees
FDA reversed prior denial and granted barrier-to-innovation waiver on March 30, 2023, after reconsideration request.
Cumberland Pharma reports 17% revenue growth to $42M in FY2022; adj. EPS $0.14
FY2022 revenue $42.0M (+17% YoY); net loss $5.6M ($0.38/sh); adj. earnings $2.1M ($0.14/sh) vs adj. loss $1.2M in 2021.
Cumberland Q3 revenue up 41% to $11.4M; net loss narrows to $0.4M
Net revenue $11.4M vs $8.1M a year ago, driven by Sancuso ($4.0M) and Kristalose ($3.9M).
Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.
Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.
On January 14, 2023, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") learned that Joey A. Jacobs, a member of Cumberland’s Board of Directors, had passed away.
Effective July 15, 2022, Cumberland Pharmaceuticals Inc. (the "Company") appointed Martin S. Brown Jr, an attorney with Adams & Reese LLP, as the newest member of its Board of Directors.
On May 31, 2022, Cumberland Pharmaceuticals Inc. ("Cumberland" or the "Company") announced the retirement of Leo Pavliv, Cumberland’s Executive Vice President, Chief Development & Operations Officer.
Max materiality 0.90 · Median 0.60 · Most common event earnings